SCHEMBL13623582

SCHEMBL13623582

CC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F

nearest known ligand 0.84

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.84
CDKL5 O76039 1/20 0.84
KCNH2 Q12809 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427684 0.93 MET (0.84) METCDKL5KCNH2
Hydrochloric Acid SCHEMBL2379468 0.92 MET (0.82) METCDKL5KCNH2
Hydrochloric Acid SCHEMBL1427191 0.92 MET (0.82) METCDKL5KCNH2
Capmatinib SCHEMBL29370685 0.91 MET (1.00) METCDKL5KCNH2
Capmatinib SCHEMBL1426819 0.91 MET (1.00) METCDKL5KCNH2
Capmatinib SCHEMBL29429714 0.91 MET (1.00) METCDKL5KCNH2
SCHEMBL1951254 0.91 MET (0.81) METCDKL5KCNH2
Capmatinib SCHEMBL30166924 0.91 MET (0.98) METCDKL5KCNH2
Capmatinib SCHEMBL1427109 0.91 MET (0.98) METCDKL5KCNH2
Capmatinib SCHEMBL30166922 0.91 MET (0.98) METCDKL5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258800-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE HOLDINGS CORPORATION 2017-09-14 US disclosed
US-20150148348-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2015-05-28 US disclosed
US-8901123-B2 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same INCYTE CORPORATION (US) 2014-12-02 US disclosed
US-20130289036-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2013-10-31 US disclosed
US-8420645-B2 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same INCYTE CORPORATION (US) 2013-04-16 US disclosed
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148348-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 MET 2/4885CDKL5 493/4885KCNH2 1162/4885
US-20130289036-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 MET 2/4885CDKL5 493/4885KCNH2 1162/4885
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 MET 2/4885CDKL5 493/4885KCNH2 1162/4885
US-20170258800-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 MET 2/4885CDKL5 493/4885KCNH2 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.